ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

ClinicalTrials.gov ID: NCT00444925

Public ClinicalTrials.gov record NCT00444925. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)

Study identification

NCT ID
NCT00444925
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
1,712 participants

Conditions and interventions

Interventions

  • fesoterodine fumarate Drug
  • placebo Drug
  • tolterodine tartrate Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2007
Primary completion
Jun 30, 2008
Completion
Jun 30, 2008
Last update posted
Mar 23, 2015

2007 – 2008

United States locations

U.S. sites
41
U.S. states
27
U.S. cities
39
Facility City State ZIP Site status
Pfizer Investigational Site Homewood Alabama 35209
Pfizer Investigational Site Huntsville Alabama 35801
Pfizer Investigational Site Mobile Alabama 36608
Pfizer Investigational Site Carmichael California 95608
Pfizer Investigational Site Orangevale California 95662
Pfizer Investigational Site San Diego California 92103-6204
Pfizer Investigational Site Aurora Colorado 80012
Pfizer Investigational Site Waterbury Connecticut 06708
Pfizer Investigational Site Miami Florida 33186
Pfizer Investigational Site Wellington Florida 33414
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Coeur d'Alene Idaho 83814
Pfizer Investigational Site Sandpoint Idaho 83864
Pfizer Investigational Site Aurora Illinois 60504
Pfizer Investigational Site West Des Moines Iowa 50266
Pfizer Investigational Site Newton Kansas 67114
Pfizer Investigational Site Shrevport Louisiana 71106
Pfizer Investigational Site Watertown Massachusetts 02472
Pfizer Investigational Site Chaska Minnesota 55318
Pfizer Investigational Site Lawrenceville New Jersey 08648
Pfizer Investigational Site Albuquerque New Mexico 87109
Pfizer Investigational Site Garden City New York 11530
Pfizer Investigational Site Mineola New York 11501
Pfizer Investigational Site Burlington North Carolina 27215
Pfizer Investigational Site Concord North Carolina 28025
Pfizer Investigational Site Huntersville North Carolina 28078
Pfizer Investigational Site Dayton Ohio 45439
Pfizer Investigational Site Allentown Pennsylvania 18103
Pfizer Investigational Site Allentown Pennsylvania 18106
Pfizer Investigational Site Pittsburgh Pennsylvania 15212
Pfizer Investigational Site Pittsburgh Pennsylvania 15213-3180
Pfizer Investigational Site East Providence Rhode Island 02914
Pfizer Investigational Site Charleston South Carolina 29425
Pfizer Investigational Site Columbia South Carolina 29201
Pfizer Investigational Site Kingsport Tennessee 37660
Pfizer Investigational Site Milan Tennessee 38358
Pfizer Investigational Site Houston Texas 77024
Pfizer Investigational Site Provo Utah 84604
Pfizer Investigational Site Chesapeake Virginia 23320
Pfizer Investigational Site Seattle Washington 98104
Pfizer Investigational Site Menomonee Falls Wisconsin 53051

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 137 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00444925, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 23, 2015 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00444925 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →